Abstract:Evidence suggests that the glycogen synthase kinase 3 (GSK3)-dictated nuclear exclusion and degradation of Nrf2 is pivotal in switching off the self-protective antioxidant stress response after injury. Here, we examined the mechanisms underlying this regulation in glomerular disease. In primary podocytes, doxorubicin elicited cell death and actin cytoskeleton disorganization, concomitant with overactivation of GSK3 beta (the predominant GSK3 isoform expressed in glomerular podocytes) and minimal Nrf2 activation. SB216763, a highly selective small molecule inhibitor of GSK3, exerted a protective effect that depended on the potentiated Nrf2 antioxidant response, marked by increased Nrf2 expression and nuclear accumulation and augmented production of the Nrf2 target heme oxygenase-1. Ectopic expression of the kinase-dead mutant of GSK3 beta in cultured podocytes reinforced the doxorubicin-induced Nrf2 activation and prevented podocyte injury. Conversely, a constitutively active GSK3 beta mutant blunted the doxorubicin-induced Nrf2 response and exacerbated podocyte injury, which could be abolished by treatment with SB216763. In murine models of doxorubicin nephropathy or nephrotoxic serum nephritis, genetic targeting of GSK3 beta by doxycycline-inducible podocyte-specific knockout or pharmacologic targeting by SB216763 significantly attenuated albuminuria and ameliorated histologic signs of podocyte injury, including podocytopenia, loss of podocyte markers, podocyte de novo expression of desmin, and ultrastructural lesions of podocytopathy (such as foot process effacement). This beneficial outcome was likely attributable to an enhanced Nrf2 antioxidant response in glomerular podocytes because the selective Nrf2 antagonist trigonelline abolished the proteinuria-reducing and podocyte-protective effect. Collectively, our results suggest the GSK3 beta-regulated Nrf2 antioxidant response as a novel therapeutic target for protecting podocytes and treating proteinuric glomerulopathies.

Inhibition of RAC Attenuates Adriamycin-induced Podocyte Injury

[New Insight in Pathogenesis of Podocyte Disfunction in Minimal Change Disease].

Rapamycin Reduces Podocyte Apoptosis and is Involved in Autophagy and Mtor/ P70S6K/4EBP1 Signaling.

Selective Inhibition of Histone Deacetylase Class IIa With MC1568 Ameliorates Podocyte Injury

Genetic and Pharmacologic Targeting of Glycogen Synthase Kinase 3 Beta Reinforces the Nrf2 Antioxidant Defense Against Podocytopathy

The RNA Binding Protein Hnrnpk Protects Against Adriamycin-Induced Podocyte Injury

Melanocortin Therapy Ameliorates Podocytopathy and Proteinuria in Experimental Focal Segmental Glomerulosclerosis Involving a Podocyte Specific Non-Mc1r-mediated Melanocortinergic Signaling.

Calcineurin inhibitors cyclosporin A and tacrolimus protect against podocyte injury induced by puromycin aminonucleoside in rodent models.

Pharmacological Melanocortin 5 Receptor Activation Attenuates Glomerular Injury and Proteinuria in Rats with Puromycin Aminonucleoside Nephrosis.

Dysfunction of the PGC-1α-mitochondria Axis Confers Adriamycin-Induced Podocyte Injury.

Pharmacological Targeting of GSK3β Confers Protection Against Podocytopathy and Proteinuria by Desensitizing Mitochondrial Permeability Transition

Minnelide Markedly Reduces Proteinuria in Mice with Adriamycin Nephropathy by Protecting Against Podocyte Injury

Human Relevance of Blocking the Rac1-TRPC5 Pathway As a Podocyte-Protective Strategy for Progressive Kidney Diseases

Inhibiting 4E-BP1 Re-Activation Represses Podocyte Cell Cycle Re-Entry and Apoptosis Induced by Adriamycin

Blocking the Rac1-TRPC5 pathway protects human podocytes

Effect of activating PKA signaling on dedifferentiation of podocytes in adriamycin-induced nephropathy mice

Α‐actinin‐4 is Involved in the Process by Which Dexamethasone Protects Actin Cytoskeleton Stabilization from Adriamycin‐induced Podocyte Injury

PP2A Protects Podocytes Against Adriamycin-induced Injury and Epithelial-to-mesenchymal Transition Via Suppressing JIP4/p38-MAPK Pathway

Cyclic AMP Prevents Decrease of Phosphorylated Ezrin/radixin/moesin and Chloride Intracellular Channel 5 Expressions in Injured Podocytes

Kindlin-2 Association with Rho GDP-Dissociation Inhibitor Α Suppresses Rac1 Activation and Podocyte Injury.

CD73 alleviates podocytes injury in adriamycin-induced nephrotic syndrome